Administration of anti-CD30 antibody-drug conjugates to non-adult humans

摘要

The present invention provides, among other things, the administration of an effective amount of an anti-CD30 ADC (antibody drug conjugate), such as brentuximab vedotin, to a non-adult human subject. Methods are provided for treating disorders characterized by pathological activity of CD30 + cells, such as in lymphoid cancer. The present invention also provides corresponding kits and products suitable for performing the methods provided by the present invention. Body surface area (BSA) equivalent dose of anti-CD30 ADC, as assessed by area under the curve (AUC), is more consistently exposed to ADC across the whole body of a non-adult human subject than the weight equivalent dose of anti-CD30 ADC The present invention is based at least in part on Applicants' discovery that [Selection figure] None